| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| T1015 |
Clinic visit/encounter, all-inclusive |
72,737 |
65,427 |
$14.29M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
89,612 |
76,434 |
$1.09M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
24,095 |
23,184 |
$624K |
| 97597 |
|
11,355 |
5,044 |
$313K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
11,873 |
11,538 |
$303K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
3,659 |
3,647 |
$198K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,299 |
2,292 |
$129K |
| 92250 |
|
1,609 |
1,609 |
$78K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
7,927 |
7,606 |
$49K |
| 20610 |
|
1,144 |
903 |
$48K |
| G0467 |
Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit |
13,297 |
10,143 |
$43K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,848 |
1,791 |
$40K |
| 95251 |
|
463 |
431 |
$27K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
2,497 |
2,390 |
$26K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
161 |
160 |
$26K |
| 90686 |
|
1,976 |
1,972 |
$25K |
| 71046 |
Radiologic examination, chest; 2 views |
1,164 |
1,159 |
$24K |
| 29581 |
|
443 |
178 |
$23K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
3,313 |
3,278 |
$23K |
| 99406 |
|
2,255 |
1,856 |
$23K |
| G2025 |
Payment for a telehealth distant site service furnished by a rural health clinic (rhc) or federally qualified health center (fqhc) only |
810 |
777 |
$22K |
| 81025 |
|
3,521 |
3,429 |
$11K |
| 81002 |
|
6,745 |
6,586 |
$11K |
| 73610 |
|
399 |
385 |
$9K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
783 |
770 |
$7K |
| 73110 |
|
291 |
261 |
$7K |
| 73630 |
|
308 |
296 |
$6K |
| 73562 |
|
311 |
300 |
$6K |
| 82948 |
|
9,391 |
8,490 |
$6K |
| 86580 |
|
1,333 |
1,270 |
$5K |
| 97802 |
|
57 |
57 |
$5K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
838 |
828 |
$5K |
| 11055 |
|
270 |
166 |
$4K |
| 73030 |
|
164 |
158 |
$3K |
| 92551 |
|
354 |
352 |
$3K |
| 29075 |
|
24 |
24 |
$2K |
| 73130 |
|
104 |
92 |
$2K |
| J3490 |
Unclassified drugs |
843 |
833 |
$2K |
| 73140 |
|
154 |
134 |
$2K |
| 73620 |
|
132 |
107 |
$2K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
48 |
47 |
$2K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
54 |
53 |
$2K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
373 |
366 |
$2K |
| A4649 |
Surgical supply; miscellaneous |
1,206 |
1,186 |
$2K |
| 73564 |
|
50 |
50 |
$2K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
43 |
43 |
$2K |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
79 |
78 |
$2K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
28 |
28 |
$1K |
| 99384 |
|
14 |
14 |
$1K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
36 |
36 |
$1K |
| 73560 |
|
64 |
51 |
$944.21 |
| 99215 |
Prolong outpt/office vis |
15 |
15 |
$774.56 |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
32 |
31 |
$673.05 |
| 73080 |
|
29 |
26 |
$660.50 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
745 |
742 |
$601.40 |
| 82274 |
|
33 |
31 |
$536.62 |
| 11721 |
|
13 |
12 |
$533.43 |
| 90715 |
|
36 |
36 |
$480.81 |
| 84443 |
Thyroid stimulating hormone (TSH) |
26 |
26 |
$469.34 |
| 73100 |
|
26 |
25 |
$403.82 |
| 90662 |
|
133 |
133 |
$366.04 |
| 90651 |
|
34 |
34 |
$359.75 |
| 90670 |
|
24 |
24 |
$285.29 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
40 |
39 |
$223.02 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
16 |
15 |
$141.96 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
28 |
28 |
$137.28 |
| 83655 |
|
17 |
17 |
$119.00 |
| 90710 |
|
13 |
13 |
$117.00 |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
12 |
12 |
$90.18 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
32 |
31 |
$83.47 |
| 85018 |
|
78 |
78 |
$65.48 |
| 96127 |
|
13 |
13 |
$63.47 |
| G0466 |
Federally qualified health center (fqhc) visit, new patient; a medically-necessary, face-to-face encounter (one-on-one) between a new patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit |
13 |
13 |
$55.48 |
| 99173 |
|
185 |
183 |
$30.96 |
| 0637 |
|
15 |
15 |
$26.47 |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
13 |
13 |
$3.92 |
| J7609 |
Albuterol, inhalation solution, compounded product, administered through dme, unit dose, 1 mg |
124 |
123 |
$0.00 |
| Z7610 |
|
261 |
258 |
$0.00 |
| 0636 |
|
95 |
72 |
$0.00 |
| 90656 |
|
38 |
38 |
$0.00 |
| 96160 |
|
47 |
46 |
$0.00 |